Hikma 2009 Results Interviews With CEO and CFO

LONDON, March 17, 2010 - Hikma Pharmaceuticals today announced 2009 preliminary results with
operating profits up 36% on the back of a strong performance from its Middle
East markets.

In a video interview on financial broadcaster www.cantos.com,
Group CEO Said Darwazah re-committed to his target of doubling the size of
the business every four years, saying, "If you look at our track record over
the last 10 or 12 years you see that we've pretty much delivered that and
I see no reason why we won't be able to continue delivering that. So my
commitment stands."

The emerging markets-based Pharma company also reported a return to
profitability in its US generics business and improving trends in its
European Injectables and Oncology businesses

Hikma also has a $300m dollar war chest for acquisitions. Group Chief
Financial Officer, Bassam Kanaan, said: "We have up to about $300m of
borrowing capacity which we can use to fund acquisitions that we plan to
make, especially in the MENA region. Anything above that, I think we will
have to explore other options for funding."

The interviews and transcripts are available now on
www.cantos.com.

Cantos.com, the online financial broadcaster, features in-depth
interviews, documentaries and webcasts with senior company executives. If you
would like to contact us, please email amanda.alexander@cantos.com or phone
+44-207-936-1352.

If you would like to contact us, please email amanda.alexander at cantos.com or phone
+44-207-936-1352